Reducing memory loss in mammals suffering from alzheimer's disease
The disclosure relates to methods and compositions for reducing memory loss. Specifically, methods of using inhibitors of GAT-3 polypeptide activity to reduce memory loss in mammals suffering from Alzheimer's disease (AD) are provided. Further provided are methods for identifying a mammal as having AD by detecting the presence of an elevated level of gamma-aminobutyric acid (GABA) within a mammal's brain.
1. A method for improving memory of a mammal having Alzheimer's disease, wherein said method comprises administering (S)-SNAP-5114 to said mammal, wherein the memory of said mammal improves following said administering.
2. The method of claim 1 , wherein said mammal is a human.
3. The method of claim 1 , wherein said method further comprises administering NNC 05-2045.
4. The method of claim 1 , wherein said memory improves by more than 20 percent.
5. The method of claim 1 , wherein said administration comprises an intravenous administration.
6. The method of claim 1 , wherein said method comprises administering an inhibitor of α5-GABA A receptor activity to said mammal.
7. The method of claim 6 , wherein said inhibitor of α5-GABA A receptor activity is L-655,708.
8. The method of claim 1 , wherein said inhibitor of α5-GABAa receptor activity is administered to said mammal after said (S)-SNAP-5114 is administered to said mammal.